New insights into the anti-diabetic actions of metformin: from the liver to the gut

Expert Review of Gastroenterology and Hepatology

Volumn 11, Issue 2, 2017, Pages 157-166

  Wu, Tongzhi ^a   Horowitz, Michael ^a   Rayner, Christopher K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

bile salt; glucose absorption; gut microbiota; hepatic glucose production; incretin hormones; Metformin

Indexed keywords

ADENYLATE KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FARNESOID X RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 5; INCRETIN; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; ORGANIC CATION TRANSPORTER 3; PEPTIDE YY; SODIUM GLUCOSE COTRANSPORTER 1; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ANTIDIABETIC ACTIVITY; BIOACCUMULATION; DIARRHEA; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; GASTROINTESTINAL TRACT; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; STOMACH EMPTYING; VOMITING; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIVER; METABOLISM; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; METFORMIN; TREATMENT OUTCOME;

EID: 85008958392     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2017.1273769     Document Type: Review

References (86)

1. Slotta KH, Tschesche E. Über Biguanide TR, II. Die blutzuckersenkende Wirkung der Biguanide. Ber Dtsch Chem Ges. 1929;62:1398–1405.
2. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease:a systematic review. JAMA. 2014;312(24):2668–2675.
3. Group U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet. 1998;352(9131):837–853.
4. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications:a systematic review. Arch Intern Med. 2008;168(19):2070–2080.
5. Andujar-Plata P, Pi-Sunyer X, Laferrere B., Metformin effects revisited. Diabetes Res Clin Pract. 2012;95(1):1–9.
6. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):550–554.
7. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–246.
8. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.
9. He L, Wondisford FE. Metformin action:concentrations matter. Cell Metab. 2015;21(2):159–162.
10. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation:results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198–205.•• This study illustrated the major contribution of the gastrointestinal actions of metformin to its glucose-lowering effect in patients with type 2 diabetes.
11. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.
12. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008;51(8):1552–1553.
13. Oh J, Chung H, Park SI, et al. Inhibition of the MATE transporter by pyrimethamine increases the plasma concentration of metformin but does not increase anti-hyperglycaemic activity in humans. Diabetes Obes Metab. 2016;18(1):104–108.
14. Morrissey KM, Stocker SL, Chen EC, et al. The effect of nizatidine, a MATE2K selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers. Clin Pharmacokinet. 2016;55(4):495–506.
15. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–614.
16. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–228.
17. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174.
18. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–1646.
19. Caton PW, Nayuni NK, Kieswich J, et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010;205(1):97–106.
20. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635–646.
21. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369.
22. Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19(12):1649–1654.
23. Zhao W, Li A, Feng X, et al. Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal. 2016;28(9):1401–1411.
24. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256–260.• This study established a novel link between metformin and hepatic glucagon signaling in mice.
25. Wu T, Ma J, Bound MJ, et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes. 2014;63(8):2776–2787.
26. Gu W, Yan H, Winters KA, et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009;331(3):871–881.
27. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–546.• This study discovered mitochondrial glycerophosphate dehydrogenase as a new therapeutic target of metformin in rats.
28. Sum CF, Webster JM, Johnson AB, et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61–65.
29. Cao J, Meng S, Chang E, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289(30):20435–20446.
30. Zhang CS, Li M, Ma T, et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab. 2016;24(4):521–522.
31. Chandel NS, Avizonis D, Reczek CR, et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 2016;23(4):569–570.
32. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422–1431.
33. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin:a GoDARTS study. Diabetes. 2009;58(6):1434–1439.
34. Stepensky D, Friedman M, Raz I, et al. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos. 2002;30(8):861–868.
35. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000;59(7):887–890.
36. Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol. 1991;43(2):120–121.
37. Sakar Y, Meddah B, Faouzi MA, et al. Metformin-induced regulation of the intestinal D-glucose transporters. J Physiol Pharmacol. 2010;61(3):301–307.
38. Lenzen S, Lortz S, Tiedge M. Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats. Biochem Pharmacol. 1996;51(7):893–896.
39. Wu T, Xie C, Wu H, et al. Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes Obes Metab. 2016. doi:10.1111/dom.12812. [Epub ahead of print].•• This study reported an inhibitory effect of metformin on glucose absorption in patients with type 2 diabetes.
40. Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35(1):95–99.
41. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39(11):1831–1834.
42. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105(4):1009–1013.
43. Wu T, Rayner CK, Horowitz M. Incretins. Handb Exp Pharmacol. 2016;233:137–171.
44. Wu T, Thazhath SS, Bound MJ, et al. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes:stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res Clin Pract. 2014;106(1):e3–e6.
45. Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011;152(12):4610–4619.
46. Cuthbertson J, Patterson S, O’Harte FP, et al. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism. 2011;60(1):52–56.
47. Bahne E, Hansen M, Bronden A, et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes Obes Metab. 2016;18(10):655–661.
48. Kim MH, Jee JH, Park S, et al. Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J Endocrinol. 2014;220(2):117–128.
49. Maida A, Lamont BJ, Cao X, et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia. 2011;54(2):339–349.
50. Duca FA, Cote CD, Rasmussen BA, et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med. 2015;21(5):506–511.•• This study established a gut-brain-liver pathway underlying metformin-induced suppression of hepatic glucose production in rats.
51. Hansen M, Bahne E, Sonne DP, et al. The acute glucose-lowering effect of metformin in patients with type 2 diabetes is partly glucagon-like peptide-1-dependent. Diabetologia. 2015;58(Suppl):S110.
52. Eissele R, Goke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992;22(4):283–291.
53. DeFronzo RA, Buse JB, Kim T, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY:results from two randomised trials. Diabetologia. 2016;59(8):1645–1654.• This paper provided mechanistic insights into the gastrointestinal-mediated glucose-lowering effect of metformin in patients with type 2 diabetes.
54. Caspary WF, Creutzfeldt W. Inhibition of bile salt absorption by blood-sugar lowering biguanides. Diabetologia. 1975;11(2):113–117.
55. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med. 1998;15(8):651–656.
56. Rudling M, Camilleri M, Graffner H, et al. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015;15:75.
57. Sonne DP, Knop FK., Comment on Xu, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015;38:1858–1867, e215.
58. Nguyen A, Bouscarel B. Bile acids and signal transduction:role in glucose homeostasis. Cell Signal. 2008;20(12):2180–2197.
59. Sonne DP, Hare KJ, Martens P, et al. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. Am J Physiol Gastrointest Liver Physiol. 2012;304(4):G413–G419.
60. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–3619.
61. Ferrannini E, Camastra S, Astiarraga B, et al. Increased bile acid synthesis and deconjugation after biliopancreatic diversion. Diabetes. 2015;64(10):3377–3385.
62. Zhang X, Liu T, Wang Y, et al. Comparative effects of bile diversion and duodenal-jejunal bypass on glucose and lipid metabolism in male diabetic rats. Obes Surg. 2016;26(7):1565–1575.
63. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. The Journal of Clinical Investigation. 2006;116(4):1102–1109.
64. Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells:a primary cell study. Cell Metab. 2008;8(6):532–539.
65. Pham H, Hui H, Morvaridi S, et al. A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells. Biochem Biophys Res Commun. 2016;475(3):295–300.
66. Wu T, Bound MJ, Standfield SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5):474–477.
67. Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012;55(9):2343–2347.
68. Wu T, Bound MJ, Standfield SD, et al. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab. 2013;98(4):E718–E722.
69. Islam KB, Fukiya S, Hagio M, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011;141(5):1773–1781.
70. Nagpal R, Kumar M, Yadav AK, et al. Gut microbiota in health and disease:an overview focused on metabolic inflammation. Benef Microbes. 2016;7(2):181–194.
71. Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–735.
72. Collado MC, Derrien M, Isolauri E, et al. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007;73(23):7767–7770.
73. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266.• This paper linked metformin therapy to the functional shift of gut microbiota in patients with type 2 diabetes.
74. Phillips LK, Deane AM, Jones KL, et al. Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol. 2015;11(2):112–128.
75. Eisner M, Berger W. Biguanides and gastric emptying in man. Digestion. 1971;4(5):309–313.
76. Naimi M, Tsakiridis T, Stamatatos TC, et al. Increased skeletal muscle glucose uptake by rosemary extract through AMPK activation. Appl Physiol Nutr Meta. 2015;40(4):407–413.
77. Gunton JE, Delhanty PJ, Takahashi S, et al. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003;88(3):1323–1332.
78. Luna V, Casauban L, Sajan MP, et al. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Diabetologia. 2006;49(2):375–382.
79. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349–1357.
80. Ciaraldi TP, Aroda V, Mudaliar SR, et al. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome:effects of pioglitazone and metformin treatment. Metabolism. 2013;62(11):1587–1596.
81. Ali S, Fonseca V. Overview of metformin:special focus on metformin extended release. Expert Opin Pharmacother. 2012;13(12):1797–1805.
82. Bytzer P, Talley NJ, Jones MP, et al. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15(1):137–142.
83. Kojima S, Tohei A, Anzai N. A role for endogenous peptide YY in tachykinin NK(2) receptor-triggered 5-HT release from guinea pig isolated colonic mucosa. Br J Pharmacol. 2012;167(6):1362–1368.
84. Wu T, Rayner CK, Young RL, et al. Gut motility and enteroendocrine secretion. Curr Opin Pharmacol. 2013;13(6):928–934.
85. Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094.
86. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501–506.